Physician profile
Ling Ma
NPI 1063617454
$6,795.70
in general payments reported to CMS, 2019-2025
46 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $1,382 · 2021: $1,693 · 2022: $95.54 · 2023: $443 · 2024: $1,427 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.57 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,180.59 | 2019-2025 | Enhertu, Datroway, Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,487.66 | 2020-2025 | |
| Medtronic, INC. | $418.22 | 2024 | Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Immunogen, INC. | $277.73 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $273.32 | 2019 | |
| Abbvie INC. | $200.62 | 2024-2025 | |
| Genentech USA, INC. | $168.19 | 2022-2025 | Tecentriq, Itovebi, Polivy |
| Glaxosmithkline, LLC. | $133.75 | 2024-2025 | Jemperli, Blenrep, Ojjaara |
| Pfizer INC. | $122.30 | 2023-2025 | |
| Astellas Pharma US INC | $121.81 | 2025 | Vyloy |
| Tempus Ai, INC | $117.37 | 2024 | |
| Iovance Biotherapeutics, INC. | $104.10 | 2024-2025 | Amtagvi |
| Tersera Therapeutics LLC | $98.22 | 2024-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $82.85 | 2019 | |
| Celgene Corporation | $81.02 | 2022-2024 | Reblozyl |
Show all 41 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.